Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA - Get Free Report)'s stock price fell 0.5% during trading on Thursday . The stock traded as low as $2.14 and last traded at $2.14. 2,898 shares changed hands during trading, a decline of 78% from the average session volume of 13,407 shares. The stock had previously closed at $2.15.
Wall Street Analyst Weigh In
IPHA has been the subject of several analyst reports. HC Wainwright reiterated a "buy" rating and issued a $11.00 target price (down previously from $11.50) on shares of Innate Pharma in a report on Thursday, April 24th. BTIG Research started coverage on shares of Innate Pharma in a report on Monday, July 28th. They set a "buy" rating on the stock.
Check Out Our Latest Analysis on IPHA
Innate Pharma Price Performance
The business's 50-day moving average price is $1.95 and its 200 day moving average price is $1.99. The company has a debt-to-equity ratio of 2.52, a current ratio of 2.60 and a quick ratio of 2.60.
About Innate Pharma
(
Get Free Report)
Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Innate Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Innate Pharma wasn't on the list.
While Innate Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
